Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Sigma Labs, Inc. (NASDAQ: SGLB) Reports Q4, Full Year 2019 Financial Results; Hosts Conference Call

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, on Tuesday reported its financial and operational results for the fourth quarter and full year ended December 31, 2019. Among other highlights, the company reported that revenue for the full year of 2019 totaled $402,000, and that $133,000, or 33% was earned in the fourth quarter. This compares to total revenue of $388,000 for the full year of 2018, of which $56,000 was earned in the fourth quarter of 2018. Sigma Labs’ Executive Chairman Mark Ruport, CEO John Rice and CFO Frank Orzechowski held a conference call to discuss the results. To listen to the replay of the call, dial 1-844-512-2921 for the toll-free replay line or 1-412-317-6671 for the international replay line and use the replay ID: 13700105. The replay is also available online. “Sigma is truly on the forefront of the next industrial revolution, addressing a major cost headwind to allow additive manufacturing technology to further scale and revolutionize many industries. We continue to see momentum from both end-users, who constantly serve as a reminder of the value of our technology, and from additive manufacturing machine OEMs, who see inherent value in integrating PrintRite3D into their machines. Revenues from either of these avenues could build rapidly, but more importantly could provide for a repeatable revenue stream with exceptional gross margins,” Sigma Labs Executive Chairman Mark Ruport stated in the news release.

To view the full press release, visit http://ibn.fm/1IpVk

About Sigma Labs

Sigma Labs, Inc. (NASDAQ: SGLB) is an emerging provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Strategic Board Appointments of Three Biotechnology and Healthcare Industry Leaders

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments, which include Brent Longnecker, CEO of Longnecker & Associates, Jose A. Moreno Toscano, CEO of LFB USA Inc, and William R. (“Will”) Wilson, Jr., chairman, president and CEO of Wilson Land & Cattle Co., are designed to strengthen Genprex as it executes on its key clinical programs, continues to build its pipeline, and evaluates future license or corporate partnership agreements. “We are honored to have Brent, Jose and Will join our Board in what we believe is a transformational time for our Company,” Genprex CEO Rodney Varner said in the news release. “Their combined experience in regulatory compliance, business development, clinical trial management, and deal structuring will be invaluable as we continue to develop gene therapy drug candidates and pursue partnerships for our drug candidates. The addition of these outstanding directors, together with our new senior executive hires and a significantly strengthened balance sheet, puts us in an excellent position to execute our plans.”

To view the full press release, visit http://ibn.fm/1KWZc

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and other serious diseases who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases. The company’s lead product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), uses the company’s unique, proprietary platform which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for Oncoprex in combination with AstraZeneca’s Tagrisso(R) for the treatment of NSCLC. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Genprex, Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Expands Leadership Team with Appointment of Accomplished Life Science Executives

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Catherine M. Vaczy as executive vice president and chief strategy officer and Michael T. Redman as executive vice president and chief operating officer. These appointments follow on the heels of Genprex’s Fast Track Designation for its lead drug candidate, its newly licensed gene therapy for diabetes, and over $26 million capital raise that will support funding of its clinical programs. “We are delighted to welcome Catherine and Michael to our executive leadership team. They join us at an exciting time as we advance our lead drug candidate into key clinical programs in non-small cell lung cancer and pursue partnership opportunities for our oncology platform and newly licensed gene therapy technology for diabetes,” Genprex CEO Rodney Varner said in the news release. “Catherine and Michael each have significant biotechnology company experience that enhances our capabilities and will be instrumental in advancing our programs. Their combined expertise in business development, corporate strategy, manufacturing, clinical trial strategy and operations and regulatory affairs will be of great value as we build Genprex into a leading gene therapy company bringing new treatment options to patients in need. We are fortunate to have raised over $26 million just prior to the current turmoil in the markets, significantly strengthening our balance sheet and well positioning us financially as we execute on our strategic plan.”

To view the full press release, visit http://ibn.fm/Et8s2

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and other serious diseases who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases. The company’s lead product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), uses the company’s unique, proprietary platform which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for Oncoprex in combination with AstraZeneca’s Tagrisso(R) for the treatment of NSCLC. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Genprex, Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $3.5 Million in Private Placement

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced its March 19, 2020, closing on its previously announced private offering of common stock and warrants resulting in gross proceeds of $3,498,612 to the Company. Per the offering, the Company sold and issued 1,650,166 shares of common stock (or common stock equivalents) and issued Series A warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating five and one-half years after the date of issuance, as well as Series B warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating two years after the date of issuance. Predictive Oncology intends to use the net proceeds for general corporate purposes.

To view the full press release, visit http://ibn.fm/vpceT

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Announces Financial Results for Q4 and Fiscal Year 2019

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2019. “We are pleased to report another quarter of healthy revenue growth and increased profitability in the fourth quarter, concluding a strong 2019 that saw Blue Hat become a U.S. listed public company while making progress in sales, business development and research and development,” Blue Hat CEO Xiaodong Chen said in the news release. “A particular highlight during the fourth quarter of 2019 was our thriving smart education business line which launched a range of exciting new AR immersive educational products for children between the ages of three and six years old. Our products are being embraced by consumers both in China and international markets, demonstrated by the popularity of ‘AR Dinosaur’ which helped Blue Hat attract a large number of visitors to our booth at the China Toy Expo in October 2019, as well as the buzz generated by our ‘AR Glow’ Interactive Glowstick product among international buyers at the 126th China Import and Export Fair. Looking forward, we intend to continue to explore both in-house development and strategic investment opportunities to strengthen our pipeline of toy and game content and maximize shareholder value, although no definitive agreements have been executed.”

To view the full press release, visit http://ibn.fm/7ptuV

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games, and toys with mobile game features. The Company’s interactive entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery.  Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the Company’s investor relations website at http://IR.BlueHatGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Blue Hat Interactive Entertainment Technology BHAT, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Sigma Labs, Inc. (NASDAQ: SGLB) Announces Award of Two US Patents for its Industry-Leading PrintRite3D(R) Technology

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, today announced that it has been awarded two U.S. patents for its industry-leading technology, PrintRite3D(R). According to the update, the patents include: U.S. Application No.: 16/234,333 Titled: Systems and Methods for Additive Manufacturing Operations; and U.S. Application No.: 16/282,004 Titled: Systems and Methods for Measuring Radiated Thermal Energy During an Additive Manufacturing Operation. “3D manufacturing will become more and more critical to the major economies of the world in order to shorten and simplify complex supply chains by manufacturing metal parts closer to home,” Sigma Labs Executive Chairman Mark K. Ruport said in the news release. “The recent crisis highlights the fact that economies that are too interdependent are subject to significant slowdowns in times of crisis. The fact that our technology could play a role in accelerating the industrialization of 3D metal printing, validates the investments that we have made in developing and commercializing our PrintRite3D(R) product.”

To view the full press release, visit http://ibn.fm/Na4GS

About Sigma Labs

Sigma Labs, Inc. (NASDAQ: SGLB) is an emerging provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – Pressure BioSciences Inc.’s (PBIO) UST Demonstration Laboratory Showcases Groundbreaking Technology

Pressure BioScience (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform-technology solutions to the worldwide life sciences and other industries, recently announced the opening of its new Ultra Shear Technology(TM) (“UST”) Demonstration Laboratory (http://ibn.fm/veoMI). An article discussing the company reads, “The main goal of the UST Demo Lab is to showcase the ability of the company’s revolutionary UST Platform to process cannabidiol (‘CBD’) oil into water-soluble nanoemulsions of superior quality. CBD nanoemulsions are expected to be more stable and offer higher bioavailability than the standard macro and microemulsions used in the vast majority of CBD products today. . . . The second objective is to invite potential purchasers of the company’s BaroShear nanoemulsification system to evaluate how their CBD and other product formulations work with the company’s revolutionary UST platform. The company expects to install and invoice the initial 12 BaroShear K45 systems in the fourth quarter of 2020.”

To view the full article, visit http://ibn.fm/jEHQt

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life-sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO | Leave a comment

Trxade Group Inc. (NASDAQ: MEDS) Has Over 11,900 Pharmacies on Trading Platform, with No Contract or Fee Obligations

  • Major first-mover advantage in proprietary web-based e-commerce platform segment
  • Penetrating U.S. independent pharmacy market with total purchases of $92 billion per annum
  • Adding 100+ pharmacies per month to its online purchasing platform

Trxade Group Inc. (NASDAQ: MEDS), an integrated drug delivery, procurement, and health care platform that offers health care buyers and sellers of pharmaceuticals procurement, currently has more than 11,900 pharmacies as registered users of its proprietary e-commerce platform. Registered users are under no contract of fee obligations when joining the ‘Supplier-to-Pharmacy’ (S2P) trading platform.

With the current number of users already on the network – serving an estimated 12 to 15 million patients indirectly through these member pharmacies , and adding about 100 new pharmacies per month, Trxade’s goal is to reach most, if not all, of the 24,000 independent pharmacies in the U.S., which have a combined annual purchasing power of more than $92 billion.

Leveraging a robust technology with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features, the platform is designed to help independent pharmacies identify the best available supplier prices for prescription drugs nationwide. The platform allows its members to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving them money by taking advantage of best purchase pricing.

This approach is part of Trxade’s efforts to be one of the driving forces behind a nationwide reduction of pharmaceutical and health care costs. To this end, the company is committed to developing its portfolio of products and services to drive value and growth for all members, employees and investors. Trading platform aside, Trxade also owns a mail order pharmacy and warehouse and drug delivery service through our Delivemeds (www.Delivmeds.com) and Bonum Health (www.BonumHealth.com) a Telehealth App.

The company recently launched a one-of-a-kind Telehealth initiative, called the ‘Bonum Health Hub’, together with wholly owned subsidiary Bonum Health, which partnered with Tampa Bay-based independent retail pharmacy chain Benzer Pharmacy. Bonum and Benzer will locate the Health Hubs in urban and rural areas lacking this type of care. The Hubs will provide capacities and technology to offer care to patients who can afford neither primary nor collaborative care.

The U.S. health care market is currently valued around $4 trillion. As the general population ages, further growth is expected, which in turn will have increasing impact on consumers as out-of-pocket expenses rise as well. Drug costs are expected to increase faster than overall health care costs and well above inflation. Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Trxade Group Inc. (MEDS) | Leave a comment

MissionIRNewsBreaks – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) Reports Changes to Executive Team; Issues Corporate Update Regarding COVID-19

Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) on Thursday announced that Peter Horvath is stepping down as chief executive officer and as a member of the Board of Directors, effective immediately. Green Growth’s current chief operating officer Randy Whitaker will serve as interim chief executive officer. In addition, the company provided an update regarding COVID-19. In accordance with recommendations of health professionals, Green Growth has decided to temporarily close all of its mall-based cannabidiol (“CBD”) kiosk shops in an effort to protect its employees and customers from unnecessary exposure. In connection with this action, the company will also suspend sales under its CBD e-commerce platform. The company’s Las Vegas, Nevada area cannabis dispensaries will stay open for business, subject to additional pandemic-related instructions from local authorities. Green Growth will continue to pursue the sale of the CBD business to The BRN Group Inc., as previously announced, and will continue to seek and assess any potential better offers per the go-shop rights included in the transaction. “I am humbled to have worked with such amazing professionals along this journey. Among those individuals is Randy Whitaker, whom I am pleased has been named as interim CEO. The company will be in good hands with such a seasoned operator at the helm, and I have full confidence in Randy to lead the company during this difficult time,” Peter Horvath stated in the news release.

To view the full press release, visit http://ibn.fm/DA0gx

About Green Growth Brands Inc.

Green Growth Brands creates remarkable experiences in cannabis and CBD. The company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and 8 Fold. The Company also has a licensing agreement with the Greg Norman(TM) Brand to develop a line of CBD-infused personal care products designed for active wellness. GGB is expanding its cannabis operations throughout the U.S., via dispensaries in Nevada, Massachusetts and Florida and the largest network of CBD shops in malls across the country and ShopSeventhSense.com. For more information, visit the company’s website at www.GreenGrowthBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to GGBXF are available in the company’s newsroom at http://ibn.fm/GGBXF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Green Growth Brands Inc. GGBXF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Jerrick Media Holdings Inc. (JMDA) Vocal Generates Unmatched Brand-Awareness Results

Jerrick Media Holding (OTCQB: JMDA), the parent company of the Vocal platform and the Vocal for Brands content studio, partnered with Luxury skin-care brand FOREO to increase awareness of its new products (http://ibn.fm/bMYp9). A recent article discussing the company reads, “As part of the campaign, Vocal paired FOREO with an existing creator on its beauty community, Blush (http://ibn.fm/AGkeu), to create a series of stories focused on FOREO’s products. The stories included detailed reviews of products and were designed to be informative for FOREO’s current audience while inspiring interest and awareness for readers from the Blush audience. . . . ‘By partnering with Vocal for its Winter 2018 campaign, FOREO drove awareness and conversions for its product line to new and existing audiences,’ the case study for the campaign reports. ‘With 36,500 reads, an average CTR of 8.4%, and an interactive female audience representing 97% of total engagement, the branded-content campaign successfully resonated with Blush creators and readers.’”

To view the full article, visit http://ibn.fm/XB2Sv

About Jerrick

Jerrick is a holding company that develops technology-based solutions. Its flagship product — Vocal — is a long-form, digital-publishing platform focused on supporting content creators by providing them with publishing tools and monetization features that are embedded within digital communities. Vocal is architected to enable targeted marketing of branded content and e-commerce opportunities embedded within long-form content. Vocal’s community sites are managed by a dedicated team, whose primary focus is on creating safe communities and identifying monetization opportunities within those communities. For more information, visit the company’s website at https://Jerrick.media.

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://ibn.fm/JMDA

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Jerrick Media Holdings Inc. JMDA, MissionIRNewsBreaks | Leave a comment